CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S20, 2014 Special supplement with the abstract book of LATINFARMA 2013 Oral Communication CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE López-Gamboa M1,2, Aguilar-Ponce JL2, Espinoza-Zamora JR2, DavalosFiesco M2, Mena-Rodríguez FJ2, Castañeda-Hernández G1. 1Departamento de Farmacología, Centro … Continue reading CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE

J Pharm Pharmacogn Res 2(Suppl. 1): S20, 2014

Special supplement with the abstract book of LATINFARMA 2013

Oral Communication

CO 038: FREQUENCY OF USE OF THE MONOCLONAL ANTIBODY RITUXIMAB ON THE NATIONAL CANCER INSTITUTE OF MEXICO: ONE YEAR EXPERIENCE

López-Gamboa M1,2, Aguilar-Ponce JL2, Espinoza-Zamora JR2, DavalosFiesco M2, Mena-Rodríguez FJ2, Castañeda-Hernández G1.

1Departamento de Farmacología, Centro de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, San Pedro Zacatenco, C.P. 07360, México D.F.
2Instituto Nacional de Cancerología; Av. San Fernando No. 22, Sol. Sección XVI, C.P. 14080, México D.F. E-mail: dralopezg@gmail.com
Abstract

Introduction: For the health care professionals and for the maker decisions staff on the hospital is very important have a real panorama about the use of the drugs in order to improve the patient attention. In Mexico for the oncology therapeutic segment, Rituximab the chimeric, anti-CD20 monoclonal antibody is registered for: a) the treatment of Non-Hodgking´s Lymphoma (CD20+); b) also combined with chemotherapy for previously untreated patients with relapsed/refractory of chronic lymphocytic leukemia.

Methods: With the aim of determine the Rituximab frequency usage on the National Cancer Institute of Mexico we made a retrospective analysis of the rituximab dispensation data from march 2012 to march 2013. Our collected data were: the pharmaceutical presentation and vials quantity of Rituximab dispensed per patient; and from the clinical record the data recorded included: clinical indication (diagnostic) result of CD20 test, weigh, height, age, and Rituximab dosage prescribed.

Results: During the twelve-month period, a total of 2663 Rituximab vials where dispensed from the Institute pharmacy, 1353 were 500 mg vials, and 1308 were 100 mg vials, distributed on 304 patients. The list of primary diagnostics included 75 different pathologies. All patients had immunohystochemical test, the 95% of the cases were positive to the CD 20 test, 4.7% of the patients had not report and 0.3% were negative to the CD20 test.

Conclusion: Even when Rituximab was prescribed for a diverse range of clinical conditions, the use of CD20 test was a standard followed on the patients, this practice showed the specific use of Rituximab.

Piceatannol-rich extract from Passiflora edulis and hyperpigmentation
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 900-910, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1717_12.5.900 Original Article Piceatannol-rich extract from Passiflora edulis Sims seeds attenuates morphological differentiation through the reduction of MITF mRNA expression and F-actin polymerization in UVB-induced hyperpigmented B16F10 cells [El extracto rico en piceatannol de las semillas de Passiflora edulis Sims atenúa la … Continue reading Piceatannol-rich extract from Passiflora edulis and hyperpigmentation
Immunostimulatory effect of a nature-derived capsule
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 892-899, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1751_12.5.892 Original Article Potential effects of Linh Loc Son hard capsule – a Vietnamese herbal combination in immunodeficiency induced by cyclophosphamide on mice [Efectos potenciales de la cápsula dura Linh Loc Son, una combinación de hierbas vietnamitas en la inmunodeficiencia inducida por … Continue reading Immunostimulatory effect of a nature-derived capsule
Epidermal growth factor receptor mutant inhibitors as NSCLC drugs
J. Pharm. Pharmacogn. Res., vol. 12, no. 5, pp. 881-891, Sep-Oct 2024. DOI: https://doi.org/10.56499/jppres23.1740_12.5.881 Original Article Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [Inhibidor del receptor del factor de crecimiento epidérmico mutante T790M-L858R-V948R de la hoja de Calophyllum inophyllum L. como posible fármaco … Continue reading Epidermal growth factor receptor mutant inhibitors as NSCLC drugs

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio